General Information of Drug (ID: DM6DEK9)

Drug Name
Stavudine
Synonyms
DdeThd; DdeTyd; Dideoxydidehydrothymidine; Estavudina; STV; Sanilvudine; Stavudinum; Zent; Zerit; Zerit Xr; Zerut XR; BMY 27857; BMY27857; D 1413; D 4T; BMY-27857; Bristol-Myers Brand of Stavudine; Bristol-Myers Squibb Brand of Stavudine; D 4T (nucleoside); Estavudina [INN-Spanish]; Sanilvudine (JAN); Stavudine, Monosodium Salt; Stavudinum [INN-Latin]; Zerit (TN); Zerit(TM); D4T & GM-CSF; D4TMBY-27857-3; Stavudine (USAN/INN); Stavudine [USAN:BAN:INN]; Stavudine [USAN:INN:BAN]; Thymine, 1-(2,3-dideoxy-beta-D-glycero-pent-2-enofuranosyl)-(7CI,8CI); 1-(2,3-Dideoxy-beta-D-glycero-2-pentenofuranosyl)thymine; 1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine; 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione; 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione; 1-[5-(hydroxymethyl)-2,5-dihydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione & Colony-stimulating factor 2; 2',3' Didehydro 3' deoxythymidine; 2',3'-Anhydrothymidine; 2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE (DDI); 2',3'-Didehydro-2',3'-dideoxythmidine; 2',3'-Didehydro-3'-deoxythimidine; 2',3'-Didehydro-3'-deoxythymidine; 3'-Azido-3'-deoxythymidine & Granulocyte-macrophage colony-stimulating factor; 3'-Deoxy-2',3'-didehydrothymidine; 3'-Deoxy-2'-thymidinene; D4T
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Approved [1]
Therapeutic Class
Anti-HIV Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 224.21
Logarithm of the Partition Coefficient (xlogp) -0.8
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [2]
Bioavailability
82% of drug becomes completely available to its intended biological destination(s) [3]
Clearance
The renal clearance of drug is 272 mL/min []
Elimination
39% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 0.8 - 1.5 hours (in adults) [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.94659 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 1% [4]
Vd
The volume of distribution (Vd) of drug is 46 +/- 21 L []
Water Solubility
The ability of drug to dissolve in water is measured as 83 mg/mL [2]
Chemical Identifiers
Formula
C10H12N2O4
IUPAC Name
1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
Canonical SMILES
CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO
InChI
InChI=1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1
InChIKey
XNKLLVCARDGLGL-JGVFFNPUSA-N
Cross-matching ID
PubChem CID
18283
ChEBI ID
CHEBI:63581
CAS Number
3056-17-5
DrugBank ID
DB00649
TTD ID
D0Z8EX
ACDINA ID
D00639
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Reverse transcriptase (HIV RT) TT84ETX POL_HV1B1 Inhibitor [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
60 kDa heat shock protein, mitochondrial (HSPD1) OTTO1Y11 CH60_HUMAN Gene/Protein Processing [7]
Adiponectin (ADIPOQ) OTNX23LE ADIPO_HUMAN Gene/Protein Processing [8]
Albumin (ALB) OTVMM513 ALBU_HUMAN Protein Interaction/Cellular Processes [9]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Gene/Protein Processing [10]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Gene/Protein Processing [11]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Gene/Protein Processing [8]
Dicarboxylate carrier SLC25A8 OTA556MK UCP2_HUMAN Gene/Protein Processing [12]
Equilibrative nucleoside transporter 3 (SLC29A3) OTGLX8XU S29A3_HUMAN Regulation of Drug Effects [13]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Gene/Protein Processing [8]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Gene/Protein Processing [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Stavudine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Cobicistat DM6L4H2 Moderate Decreased metabolism of Stavudine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Zalcitabine DMH7MUV Moderate Increased risk of peripheral neuropathy by the combination of Stavudine and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [15]
Coadministration of a Drug Treating the Disease Different from Stavudine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Stavudine and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [14]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Stavudine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [16]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Stavudine and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [17]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Stavudine and Cannabidiol. Epileptic encephalopathy [8A62] [18]
Ribavirin DMEYLH9 Moderate Decreased metabolism of Stavudine caused by Ribavirin. Hepatitis virus infection [1E50-1E51] [19]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Stavudine and Brentuximab vedotin. Hodgkin lymphoma [2B30] [20]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Stavudine and Mipomersen. Hyper-lipoproteinaemia [5C80] [21]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Stavudine and Teriflunomide. Hyper-lipoproteinaemia [5C80] [22]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Stavudine and BMS-201038. Hyper-lipoproteinaemia [5C80] [23]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Stavudine and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [24]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Stavudine and Idelalisib. Mature B-cell leukaemia [2A82] [25]
Thalidomide DM70BU5 Moderate Increased risk of peripheral neuropathy by the combination of Stavudine and Thalidomide. Multiple myeloma [2A83] [15]
Orlistat DMRJSP8 Moderate Altered absorption of Stavudine caused by Orlistat. Obesity [5B80-5B81] [26]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Stavudine and Leflunomide. Rheumatoid arthritis [FA20] [22]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Stavudine and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [18]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Stavudine and Naltrexone. Substance abuse [6C40] [27]
⏷ Show the Full List of 16 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
FD&C blue no. 1 E00263 19700 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Magnesium stearate E00208 11177 lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 15 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Stavudine 15 mg capsule 15 mg Oral Capsule Oral
Stavudine 30 mg capsule 30 mg Oral Capsule Oral
Stavudine 20 mg capsule 20 mg Oral Capsule Oral
Stavudine 40 mg capsule 40 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2 BDDCS applied to over 900 drugs
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). Int J Biochem Cell Biol. 2004 Sep;36(9):1687-705.
7 Lon protease and eiF2 are involved in acute, but not prolonged, antiretroviral induced stress response in HepG2 cells. Chem Biol Interact. 2016 May 25;252:82-6. doi: 10.1016/j.cbi.2016.03.021. Epub 2016 Apr 1.
8 Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther. 2007;12(4):489-500.
9 Binding of anti-HIV drugs to human serum albumin. IUBMB Life. 2004 Oct;56(10):609-14. doi: 10.1080/15216540400016286.
10 Stavudine selectively induces apoptosis in HIV type 1-infected cells. AIDS Res Hum Retroviruses. 1997 Jan 20;13(2):193-9. doi: 10.1089/aid.1997.13.193.
11 Longitudinal effects of thymidine analogues on mtDNA, mtRNA and multidrug resistance (MDR-1) induction in cultured cells. J Antimicrob Chemother. 2008 May;61(5):1048-52. doi: 10.1093/jac/dkn067. Epub 2008 Feb 28.
12 Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther. 2003 Aug;8(4):323-31.
13 Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol. 2009 Apr;296(4):G910-22. doi: 10.1152/ajpgi.90672.2008. Epub 2009 Jan 22.
14 Cerner Multum, Inc. "Australian Product Information.".
15 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
16 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
17 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
18 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
19 Guyader D, Poinsignon Y, Cano Y, Saout L "Fatal lactic acidosis in a HIV-positive patient treated with interferon and ribavirin for chronic hepatitis C." J Hepatol 37 (2002): 289-91. [PMID: 12127440]
20 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
21 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
22 Canadian Pharmacists Association.
23 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
24 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
25 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
26 MHRA. Medicines and Healthcare Products Regulatory Agency "Orlistat: theoretical interaction with antiretroviral HIV medicines.".
27 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.